"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label takeover target. Show all posts
Showing posts with label takeover target. Show all posts

Monday, August 25, 2025

Intellia Therapeutics (NTLA) — Investor Brief (Aug 2025) - A leader in Crispr/Gene editing advancements!

 


As NTLA's phase 3 trials continue to show signs of real breakthroughs, there may eventually be takeover offers. (Speculation)

Full disclosure: We are long NTLA!

Intellia Therapeutics (NTLA) — Investor Brief (Aug 2025)

What They Do

  • Leader in CRISPR gene editing.

  • Focused on one-time treatments for serious diseases, using lipid nanoparticles (LNPs) to deliver CRISPR directly into the body.

  • First company to show human proof that CRISPR can work safely in vivo (inside the body).

Key Drugs in Development

  1. nex-z (ATTR Amyloidosis)

    • Targets a deadly heart and nerve disease.

    • In Phase 3 trials now.

    • Competes with Pfizer (tafamidis), BridgeBio (acoramidis), and Alnylam (Amvuttra).

    • Big advantage if proven: a single treatment vs. lifelong pills/injections.

  2. lonvo-z (HAE – Hereditary Angioedema)

    • Rare, painful swelling disorder.

    • In Phase 3 trials, with FDA filing expected in 2026.

    • Current drugs (Takeda’s Takhzyro, CSL’s Andembry) require regular injections. Intellia aims for a one-time permanent fix.

Partnerships

  • Regeneron: Co-develops ATTR drug, but keeps 25% of profits.

  • Other smaller partnerships (Novartis, AvenCell) give extra validation.

Financial Snapshot (Q2 2025)

  • Cash: $630M (enough into early 2027).

  • Quarterly revenue: $14M (partnerships).

  • Quarterly loss: $101M (normal for biotech).

  • Shares: ~105M.

Why It Matters

  • ATTR market: Pfizer’s tafamidis alone made $5.4B in 2024.

  • HAE market: Already over $1B+ yearly and growing.

  • If Intellia succeeds, these are multi-billion dollar markets with limited competition for one-time cures.

Potential Buyers

  • Regeneron: Most likely buyer (already partner, would keep all ATTR profits).

  • Takeda: HAE leader; may want to defend franchise.

  • CSL: Just launched a new HAE drug but could be disrupted.

  • Pfizer: ATTR giant, could buy to protect tafamidis sales.

  • Other big pharma (AstraZeneca, Roche, GSK) could also step in.

Buyout Scenarios

  • Current stock price: ~$11–12/share.

  • If late-stage trials succeed, potential takeout offers could land $28–$57/share (150%–400% upside).

  • Upside comes from:

    • Clear Phase 3 wins.

    • Big Pharma wanting to protect/expand rare disease franchises.

    • Intellia being one of the few with proven in-body CRISPR results.

Risks

  • Competition is fierce: ATTR already has 3 approved drugs.

  • Payers/insurance: One-time therapy pricing will face tough negotiations.

  • Cash burn: Enough until 2027, but commercialization will need more funding.

  • Profit share: ATTR economics partly belong to Regeneron.

Bottom Line

Intellia sits at the intersection of category-defining technology and late-stage assets in two sizable rare-disease markets. With clear Phase 3 wins, especially in HAE and ATTR-CM, we think (i) Regeneron is the most logical acquirer (economics synergy), with Takeda and CSL plausible strategic bidders given franchise logic; and (ii) a reasonable buyout range would center around $28–$57/share, skewing higher if both programs hit convincingly and a strategic (vs. financial) buyer leads the process.



Posted by at No comments:
Labels: , , , , ,

Thursday, July 10, 2025

Why Analysts are overwhelmingly bullish on Cabaletta Bio (CABA)

 



Ed Note: I like to point out sometimes that, some penny stocks should not be overlooked. A prime example of that is our buy in 2 years ago of QBTS at .41c (today trading at $16)  Albeit, Bio Tech is not as dynamic as Quantum tech, I believe that CABA may be in the sites of some of the big dogs in the space for it's cutting edge technology currently on the verge of proving itself!
Onward...

Analysts are overwhelmingly bullish on Cabaletta Bio (CABA) for several compelling reasons:

1. Stellar Clinical Data from RESET Trial

  • Cantor Fitzgerald highlighted new data showcased at EULAR Barcelona, reporting that 87% of patients (13/15) with ≥3 months follow-up discontinued background therapy, with only mild (Grade 1) cytokine release syndrome—deemed “stellar” efficacy 

  • William Blair (Sami Corwin) and Guggenheim (Yatin Suneja) have reiterated or raised “Buy” ratings based on these clinically meaningful outcomes 

2. Significant Upside in Price Targets

  • The average 12‑month analyst target is around $14.43–$16.21, implying a potential upside of 744–848% from the current ~$1.70 level 

  • The range of targets spans from as low as $3 to as high as $25–$28, reflecting both optimism and varying risk perspectives 

3. Strong Analyst Ratings Consensus

  • Of the approx. 8–11 analysts covering CABA, 7–8 hold “Buy” or “Strong Buy” ratings, with only a single “Hold” from Wells Fargo 

  • Recent support includes: HC Wainwright reaffirmed at $25 TP, Guggenheim boosted theirs to $25, and Citigroup maintained a “Strong Buy” with a $13 → $17 →$13 adjustment 

4. Improved Liquidity & Robust Financing

  • The company recently raised ~$100 million via a stock/warrant offering at $2.00 per share, extending their cash runway into H2 2026 and strengthening financial resilience 

  • InvestingPro notes this offering took place while analysts continued to view the stock as undervalued, with various targets between $3 and $28 

  • Technical indicators, like the RS Rating climbing from 79 to 83, suggest growing price momentum and positioning among biotech stocks showing early breakout behavior 

🧠 Summary

Analysts’ bullish stance on Cabaletta Bio reflects:

  • Strong clinical results reinforcing the promise of their lead CAR‑T therapy (rese-cel) in autoimmune diseases;


  • Large projected upside baked into current valuations with a wide range of price targets;

  • Firm consensus leaning heavily toward buys;

  • Financial stability from successful fundraises;

  • Positive technical trends, all contributing to the bullish narrative.

That said, it’s important to remember CABA remains an early-stage biotech:

  • It carries typical clinical and execution risks;

  • The cash burn rate remains elevated, even with the recent offering;

  • Any hiccups in clinical trials or regulatory delays could negatively impact momentum.

Overall, the analyst enthusiasm stems from strong data, hefty upside potential, and secured financing, signaling high risk but potentially high reward.

There’s been no credible reporting that a Big Pharma company is preparing to buy out Cabaletta Bio (CABA) at this time. Here's what we do know:

🔍 What Analysts & Industry Think

  • Strategic Attractor – Cabaletta is pioneering an autologous CAR‑T therapy (“rese‑cel”) for autoimmune diseases—an emerging field where major pharma firms are actively scouting, as noted in a recent SWOT analysis that flagged Cabaletta as a “potentially attractive acquisition target” due to its first‑mover advantage in CD19 auto‑CAR‑T and promising early reads 

  • Raised Visibility through Progress – The company recently strengthened its financial position (~$164M in cash as of end‑2024 Investing.com), expanded manufacturing agreements (e.g., Lonza), hit key milestones across indications like lupus, myositis, and multiple sclerosis, and aligned with FDA toward registrational filing—these are all strategic signals that put Cabaletta on the radar for partnering or acquisition discussions

✅ Why a Takeover Could Happen

  1. Big Pharma Gaps – Companies with deep pipelines in autoimmune and CAR‑T therapies (e.g., Roche, Novo Nordisk, Pfizer, Novartis, Gilead) might seek to augment their platforms quickly via a late-stage asset like rese‑cel.

  2. Strategic Fit – Cabaletta’s lead program, combined with its CDMO partnerships and FDA Fast Track designations, makes it a more plug‑and‑play candidate for firms looking to expand into cell therapies.

  3. Relatively Small Market Cap – With a ~US$100–160 M market cap, any acquisition would be modest for a Big Pharma company, making it financially easier to digest even with premium.

  4. (Ed note: Basically a rounding error for one of the Big Dogs)

🎯 Who Could Be Interested?

While there's no public confirmation, likely candidates include:

  • Roche – Active in autoimmune (e.g., Rituxan, bispecific antibodies) and cell therapy innovation.

  • Novartis / Gilead (via Kite) – Both have existing CAR‑T programs, and Gilead has deeper autoimmune ambitions.

  • Pfizer / Novo Nordisk – Both are stepping into cell therapy and autoimmune disease; a targeted acquisition could give them a boost.

⚠️ Caution: There Are No Concrete Offers Yet

  • ⚪ No recent rumors, terms sheets, LOIs, or insider leak stories in major biotech news.

  • ⚪ Cabaletta hasn’t announced any active M&A process or engagement with strategic buyers.

🧭 Bottom Line

While Cabaletta Bio is increasingly visible as an attractive acquisition candidate—thanks to strong data, FDA alignment, manufacturing scale-up, and untapped CAR‑T potential—there are currently no public indications that Big Pharma is preparing a takeover.

If Cabaletta continues to deliver pivotal data, especially as it moves toward registrational trials in 2026–2027, it could surface on the radar of firms like Roche, Novartis, Gilead, Pfizer, or Novo Nordisk. But for now, any buyout talk remains speculative and premature.

What to watch next:

Posted by at No comments:
Labels: , , , , , , , , , , ,

Monday, March 24, 2025

Been adding to CABA Bio stock this month. Here's why!

 


Ed Note:

I often say that, some penny stocks should not be overlooked just because they are penny stocks.

CABA is one of those !

--------------------------------------------------------------------------------------------------------------

Cabaletta Bio, Inc. (ticker: CABA) 

is a clinical-stage biotechnology company dedicated to developing targeted cell therapies for autoimmune diseases. Their leading candidate, resecabtagene autoleucel (rese-cel), is an investigational CD19-CAR T cell therapy aimed at treating conditions such as systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis. ​

In their third-quarter 2024 financial report, Cabaletta Bio disclosed research and development expenses of $26.3 million and general and administrative expenses of $6.8 million. As of September 30, 2024, the company held $183.0 million in cash, cash equivalents, and short-term investments, projecting sufficient funds to support operations into the first half of 2026. ​TipRanks

Recent clinical updates have shown promising outcomes for rese-cel. In February 2025, Cabaletta Bio reported that among the first 10 patients treated across various autoimmune indications, 90% experienced either no cytokine release syndrome (CRS) or only grade 1 (fever) CRS, and 90% had no instances of immune effector cell-associated neurotoxicity syndrome (ICANS). Additionally, deep B cell depletion was observed in all patients post-treatment, with B cell repopulation typically commencing around two months after infusion. ​Yahoo Finance

As of March 24, 2025, Cabaletta Bio's stock is trading at $1.70 per share, reflecting a slight decrease from the previous close. The stock has experienced significant volatility over the past year, with a 52-week range between $1.71 and $24.67. ​Barron's

The company's strategic priorities for 2025 include aligning with the FDA on registrational trial designs for rese-cel, enrolling and dosing patients across multiple disease-specific cohorts in the RESET clinical development program, and advancing innovations to enhance patient access and experience. ​GlobeNewswire

While Cabaletta Bio has demonstrated encouraging clinical progress, its viability and future prospects are contingent upon continued successful trial outcomes, regulatory approvals, and effective commercialization strategies. Investors should consider the inherent risks associated with investing in clinical-stage biotechnology firms, including potential delays or failures in clinical development and regulatory processes.​Yahoo Finance

Cabaletta Bio (CABA) could be a viable takeover target for several reasons, particularly for larger biotech or pharmaceutical companies looking to expand their autoimmune disease portfolios or cell therapy platforms. Here's an analysis of its viability as a target and potential suitors:

🔍 Why CABA Might Be a Takeover Target

  1. Differentiated Platform (CARTA™):
    Cabaletta’s use of CAR-T for autoimmune diseases sets it apart. While CAR-T has been primarily used in oncology, Cabaletta is applying it to autoimmunity, a space with high unmet needs and blockbuster potential.

  2. Positive Early Clinical Data:
    The early data on rese-cel (CD19-CAR-T) has shown promising safety and efficacy signals in lupus, myositis, systemic sclerosis, and myasthenia gravis—all large markets with limited curative options.

  3. Strong Cash Position:
    With ~$183 million in cash as of Q3 2024 and a relatively low burn rate, Cabaletta can fund operations into H1 2026. This gives a buyer a de-risked financial runway.

  4. Small Market Cap:
    Trading under $2 per share with a market cap significantly lower than biotech peers in autoimmune cell therapy, CABA is affordable for many potential acquirers, especially in a consolidating market.

🤝 Who Might Be Interested in Acquiring CABA?

🧬 1. Roche / Genentech

  • Deep expertise in autoimmune and immunology, including rituximab and Actemra.

  • Has shown interest in next-gen B-cell targeting and CAR-T beyond oncology.

  • CABA’s lupus and MS targets align well with Roche’s immunology strategy.

💉 2. Bristol Myers Squibb (BMS)

  • Invested heavily in CAR-T through Abecma and Breyanzi.

  • Recently expanded into autoimmune disorders (e.g., Zeposia for MS).

  • CABA would complement both their cell therapy and autoimmune portfolio.

🧪 3. Novartis

  • Owns Kymriah (a CAR-T therapy) and has experience navigating the cell therapy regulatory path.

  • Could apply its global scale and manufacturing capabilities to CABA’s autoimmune-focused pipeline.

🧬 4. Johnson & Johnson (Janssen)

  • Aggressively expanding in autoimmune and rare diseases.

  • Partnered in the past with Legend Biotech for CAR-T in cancer (Carvykti).

  • Could see CABA as a way to enter autoimmune CAR-T leadership.

🧫 5. Gilead Sciences / Kite Pharma

  • Pioneer in CAR-T with Yescarta, but with limited non-oncology pipeline.

  • May seek diversification via autoimmune applications to sustain long-term CAR-T returns.

🧠 6. Biogen

  • Recently active in neurology and autoimmune (e.g., MS drugs).

  • Could see CABA as an entry into cell therapy for neuro-autoimmune conditions like myasthenia gravis.

📉 What Could Hold Back a Takeover?

  • Still early-stage: Most candidates are in Phase 1 or early Phase 2.

  • Manufacturing complexities: CAR-T therapy production and delivery are resource-intensive.

  • Regulatory risk: Applying CAR-T to autoimmune disease is relatively new, so approval pathways are less defined.

🧭 Summary

Cabaletta Bio is a compelling acquisition target in a growing niche—cell therapy for autoimmune diseases. Its unique platform, strong early data, and relatively low valuation make it attractive to major players in biotech and pharma, particularly those with an existing CAR-T infrastructure or autoimmune drug pipeline.

Institutional Ownership Overview

Based on recent filings and data summaries:

  • Institutional ownership ranges from ~53–63% of outstanding shares, with ~42–44 million shares held by institutions (13F data: 42.9 M shares; 62.97% per Investing.com) 

  • Approximately 110–234 institutional investors have held CABA over the past 24 months (Fintel: 234 owners; MarketBeat: 110 active over 2 years) 

📋 Top Institutional Shareholders (Equity Only, via 13F / Public Disclosures)

  1. Citadel Advisors LLC – disclosed 4.82 million shares (~5.20%) as of June 20, 2025 (13G filing) 

  2. Bain Capital Life Sciences Investors, LLC – holds ~2.76 million shares (~5.17%) as of Mar 31, 2025 T. Rowe Price Investment Management – among top holders at ~8.36% (~4.46 M shares) BlackRock, Inc. – owns ~6.47% (~3.45 M shares)

  3. Adage Capital Partners – holds ~5.69% (~3.03 M shares) The Vanguard Group – around ~5.33% (~2.84 M shares) .

  4. Jennison Associates LLC – ~4.56% (~2.43 M shares) 

Other notable asset managers include Commodore Capital, Cormorant Asset Management, Morgan Stanley, Venrock, Sofinnova, Redmile, Perceptive Advisors, and Fred Alger among active participants 

Summary Table

Institutional HolderStake %Shares (Approx.)
Citadel Advisors LLC5.20%4.82 M
Bain Capital Life Sciences Investors, LLC5.17%2.76 M
T. Rowe Price Investment Mgmt8.36%~4.5 M
BlackRock, Inc.6.47%~3.4 M
Adage Capital Partners5.69%~3.0 M
Vanguard Group5.33%~2.8 M
Jennison Associates4.56%~2.4 M

📝 Key Takeaways

  • Citadel Advisors is the largest disclosed institutional investor with over 5% ownership via 13G.

  • Bain, T. Rowe Price, BlackRock, Adage, Vanguard, and Jennison are major long-only holders.

  • In total, 50+ million shares are under institutional control—a majority of the float.

  • Smaller funds like Sofinnova, Perceptive, Commodore, Cormorant, Fred Alger, Redmile, etc., also have meaningful stakes and active trading.

Related Articles in 2025:

Will the New developments from Cabaletto Bio (CABA) make it a takeover target? Stay tuned!




Posted by at No comments:
Labels: , , , , , , , , , , , ,

Tuesday, February 18, 2025

Will the New developments from Cabaletto Bio (CABA) make it a takeover target? Stay tuned!

 



Investment & Business Report: Cabaletta Bio (NASDAQ: CABA)

Company Overview: Cabaletta Bio is a clinical-stage biotechnology company focused on developing T cell therapies for autoimmune diseases. The company’s lead product candidate, resecabtagene autoleucel (rese-cel, formerly CABA-201), is part of the RESET clinical development program targeting systemic lupus erythematosus (SLE), lupus nephritis (LN), dermatomyositis, and systemic sclerosis.

Recent Developments:

  • Clinical Data Announcement:

    • Today, Cabaletta Bio announced updated clinical data from the first 10 patients dosed with rese-cel, presented at the 2025 AAAS Annual Meeting in Boston and set to be presented at the 5th International Conference on Lymphocyte Engineering in Munich.

    • Data revealed that patients demonstrated deepening clinical responses over time. Three SLE patients achieved DORIS remission, the first LN patient achieved complete renal response, and the first dermatomyositis patient showed a major Total Improvement Score (TIS) improvement.

    • All patients were able to discontinue immunosuppressants and either stop or taper steroid use.

    • The safety profile appears strong, with 90% of patients experiencing no cytokine release syndrome (CRS) or only mild (Grade 1) CRS, and no reported cases of severe immune effector cell-associated neurotoxicity syndrome (ICANS).

  • Analyst Ratings & Price Target:

    • HC Wainwright & Co. has maintained a Buy rating for Cabaletta Bio with a price target of $25.00 per share, highlighting the potential of rese-cel to become a transformative treatment for autoimmune diseases.

    • Analysts covering the stock emphasize its significant upside potential, given the compelling clinical data and promising trajectory toward regulatory discussions with the FDA.

Stock Performance:




  • As of February 18, 2025, CABA is trading at $2.455 per share, reflecting a -9.41% daily change.

  • The intraday high reached $2.90, with a low of $2.445.

  • Market capitalization stands at approximately $132.46 million.

  • Trading volume reached 1.28 million shares.

Growth Potential & Market Impact:

  • Cabaletta Bio’s approach using engineered T cell therapy to potentially provide durable, drug-free clinical responses is a novel and potentially groundbreaking advancement in treating autoimmune diseases.

  • Given the lack of effective long-term treatments for conditions like SLE, lupus nephritis, and dermatomyositis, rese-cel could be a game-changer if it continues to show positive results.

  • The company’s strategy to align with the FDA based on new data increases the likelihood of advancing toward pivotal trials and potential regulatory approval.


Potential Buyout Considerations:

  • Attractive Valuation: With a market cap of $132.46 million and a price target of $25 per share, Cabaletta Bio appears undervalued, making it an attractive acquisition target for larger pharmaceutical companies.

  • Strong Clinical Data: The deepening clinical responses in autoimmune diseases without the need for immunosuppressants position rese-cel as a high-value asset.

  • Industry Trends: The recent $1.7 billion acquisition of Inhibrx by Sanofi signals growing interest in autoimmune-focused cell therapies, increasing the likelihood of M&A activity around Cabaletta Bio.

  • Potential Acquirers: Large pharmaceutical companies such as Gilead Sciences, Novartis, Bristol-Myers Squibb, Sanofi, and Vertex Pharmaceuticals could view CABA as a strategic fit for expanding their cell therapy portfolios.

  • Buyout Probability: While an acquisition is not guaranteed, Cabaletta Bio’s promising clinical data and undervalued stock position make it a highly viable M&A target in the mid-to-long term.

Investment Considerations:

  • Strengths: Strong clinical data, growing analyst confidence, significant unmet need in autoimmune diseases, potential for transformational therapy, and increasing interest from potential acquirers.

  • Risks: Early-stage clinical development, regulatory uncertainties, and competition in the autoimmune therapy space.

Conclusion: Cabaletta Bio is positioning itself as a leader in the T cell therapy space for autoimmune diseases. With strong clinical data, a robust safety profile, significant analyst-backed upside potential, and growing M&A interest in autoimmune cell therapies, CABA presents a compelling investment opportunity. However, investors should remain mindful of clinical and regulatory risks as the company advances its development programs, as well as potential M&A opportunities that could impact its long-term valuation.

How Beam Therapeutics (BEAM) in collaboration with researchers at the University of Pennsylvania and Children’s Hospital of Philadelphia saved baby KJ

Posted by at No comments:
Labels: , , , , , , , , , ,

Will 2025 bring a buyout offer for Viking Therapeutics and their cutting edge drug pipeline? Stay tuned!

 



Viking Therapeutics (VKTX) – Investment & Business Report (February 2025)

Company Overview

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders. The company's leading drug candidates target obesity, non-alcoholic steatohepatitis (NASH), and X-linked adrenoleukodystrophy (X-ALD), placing it in direct competition with major players in the weight-loss and metabolic disorder markets.


Financial Overview

  • Cash on Hand: As of December 31, 2024, Viking reported $903 million in cash, cash equivalents, and short-term investments, up from $362 million at the end of 2023.
  • Q4 2024 Revenue: Viking remains in the pre-commercialization stage and has no product sales.
  • Net Loss: $24.9 million (Q4 2024), up from $22.5 million (Q4 2023), reflecting increased R&D expenses.
  • R&D Expenses: $31 million (Q4 2024), up 51% YoY, driven by manufacturing and trial expenses.

The company's strong cash position is a key strength, allowing it to fund operations and clinical trials without immediate dilution concerns.

Key Pipeline Candidates and Technological Advancements

1. VK2735 (GLP-1/GIP Dual Agonist for Obesity Treatment)

  • Viking’s lead obesity drug candidate, VK2735, is a GLP-1/GIP receptor dual agonist, similar to Novo Nordisk's Wegovy and Eli Lilly’s Mounjaro.
  • Latest Update: Viking initiated a Phase 2 trial for the oral tablet formulation of VK2735 in early 2025, following positive Phase 1 results that showed significant weight loss and good tolerability.
  • Analysts expect this drug to be a major competitor in the booming obesity drug market.

2. VK2809 (Thyroid Beta Agonist for NASH)

  • Phase 2b VOYAGE trial met primary and secondary endpoints, with significant reductions in liver fat and NASH markers.
  • The drug is an alternative to Madrigal Pharmaceuticals’ Resmetirom, which recently received FDA approval for NASH treatment.

3. VK0214 (For X-Linked Adrenoleukodystrophy - X-ALD)

  • Phase 1b trials showed safety and efficacy in reducing very long-chain fatty acids, which are toxic in X-ALD.

Viking is strategically focusing on obesity and metabolic disorders, which represent high-growth markets, particularly given the surging demand for effective weight-loss treatments.

Market Position and Analyst Sentiment


  • Analyst Ratings: 14/14 analysts rate Viking as a BUY.
  • Price Target Range: $38 to $164, with an average of $99.29.
  • Jefferies Target: $110, citing Viking's potential in GLP-1/GIP drug development.

Competitive Landscape and Risks

  • Competition from Novo Nordisk (NVO) and Eli Lilly (LLY): Viking is entering a highly competitive obesity drug market dominated by Wegovy (Novo Nordisk) and Zepbound (Eli Lilly).
  • Merck’s Entry into the Market: In late 2024, Merck signed a $2.01 billion deal with Hansoh Pharma for an obesity treatment, creating additional competition.
  • Regulatory Risks: Viking's drugs are still in early-to-mid-stage trials, meaning any safety issues or delays in clinical trials could negatively impact stock value.

Acquisition Potential

Given Viking's strong pipeline and robust cash reserves, the company is considered a potential acquisition target for larger pharmaceutical companies looking to expand in the obesity or metabolic disorder markets.

Conclusion: Investment Outlook
✅ Strengths:

  • Strong cash reserves ($903 million)
  • High potential for its obesity and NASH treatments
  • Positive analyst outlook ($99.29 average price target)

⚠ Risks:

  • No revenue yet (still in clinical development)
  • High competition from Novo Nordisk, Eli Lilly, and Merck
  • Regulatory approval uncertainty

Final Take:

Viking Therapeutics is a high-risk, high-reward biotech stock with significant upside potential if its obesity and NASH drugs progress successfully. Investors should monitor trial data, competition, and potential partnerships or buyout offers in the coming months.

Ed Note:

We are long $VKTX Stock!

More Pharma Stocks:



Posted by at No comments:
Labels: , , , , , , , , , , , , ,

Thursday, February 6, 2025

Chargepoint is trading today as a penny stock!

 


Feb 11th 2025

We have been "Stopped out" of Chargepoint shares.

O U C H !!!  Speculation can hurt, even if it is only 1% of your portfolio!

Who might be interested in Acquiring Chargepoint's EV charging network?

Posted by at No comments:
Labels: , , , , , ,

Friday, January 10, 2025

As the necessity for Quantum Communication grows, there is one microcap company that may become a crucial acquisition target!


Before reviewing this article, you may wish to, at first, review our previous article on this subject found at:  

Quantum communication, and the "Little company that could"!


Will Mynaric (MYNA) become a Takeover target?

The German engineers and scientists at MYNA have developed some pretty convincing tech advances in Quantum Laser communication as the Space race heats up.


If Mynaric were to become an acquisition target, several types of companies might show interest, depending on their strategic goals in quantum communication, laser technology, or satellite-based communication systems. Below are potential acquirers, categorized and ranked based on strategic alignment, financial resources, and market positioning:

1. Aerospace and Defense Giants

These companies are heavily invested in satellite communication, laser technology, and secure data transmission systems.

Key Candidates:

  1. Airbus Defence and Space

    • Why? Airbus is already a major player in satellite communication and owns Tesat-Spacecom, Mynaric’s closest competitor. Acquiring Mynaric would strengthen its portfolio, particularly in standardizing laser communication for mega-constellations.
    • Positioning: Well-funded and already active in optical communications.

  2. Northrop Grumman

    • Why? Northrop has collaborated with Mynaric in the past and has a strong presence in defense and satellite manufacturing. Owning Mynaric could help Northrop integrate advanced optical communication systems into its products.
    • Positioning: Established defense contractor with deep pockets and a history of strategic acquisitions.

  3. Lockheed Martin

    • Why? Lockheed Martin is a leader in defense and satellite systems. Mynaric’s laser communication technology aligns with Lockheed’s interest in multi-domain operations and secure communications.
    • Positioning: Strong financials and global influence in aerospace and defense.

  4. Raytheon Technologies

    • Why? Raytheon has a growing interest in space and secure communication. Mynaric’s technology would enhance its offerings in defense communication networks.
    • Positioning: Focused on advanced technology for military and government contracts.

2. Satellite and Space Communication Companies

Satellite operators and manufacturers need laser communication to ensure the scalability and efficiency of their constellations.

Key Candidates:

  1. SpaceX (Starlink) (unlikely)

    • Why? SpaceX relies on laser communication for its inter-satellite links in Starlink. Acquiring Mynaric could secure a supply of advanced, standardized optical terminals for its growing constellation.
    • Positioning: SpaceX has the resources and strategic alignment but typically prefers to develop in-house solutions.

  2. Amazon (Project Kuiper)

    • Why? Amazon is heavily investing in Project Kuiper, its satellite internet constellation. Mynaric’s expertise could accelerate Amazon’s deployment of high-bandwidth, low-latency laser links.
    • Positioning: Amazon’s deep financial resources make it a likely contender.

  3. SES or Intelsat

    • Why? These established satellite operators are evolving toward optical communication systems to remain competitive in the era of mega-constellations.
    • Positioning: Both companies have partnerships with optical communication providers but may seek vertical integration.

3. Quantum Technology Companies

Quantum communication firms could acquire Mynaric to expand their capabilities into classical laser communication systems, bridging quantum and classical networks.

Key Candidates:

  1. ID Quantique

    • Why? A leader in quantum-safe communication systems, ID Quantique could integrate Mynaric’s laser communication systems to complement its quantum technologies.
    • Positioning: Synergy between secure quantum and classical communication.

  2. Arqit Quantum

    • Why? Arqit specializes in quantum encryption. Mynaric’s optical terminals could enhance its capabilities for satellite-based quantum communication.
    • Positioning: Focused on future-proofing communication networks.

4. Technology and Telecommunications Giants

Tech companies are increasingly investing in space and advanced communication systems to secure market leadership in data transmission.

Key Candidates:

  1. Alphabet (Google)

    • Why? Google has a history of investing in advanced communication technologies (e.g., Project Loon). Mynaric could play a role in its ambitions for space-based or terrestrial high-speed networks.
    • Positioning: Financially capable and strategically aligned with cutting-edge tech.

  2. Amazon Web Services (AWS)

    • Why? AWS Ground Station is expanding its satellite services. Mynaric could bolster Amazon’s position in ground-to-satellite communication.
    • Positioning: Aggressive investment in satellite technologies.

  3. Cisco

    • Why? As a global networking leader, Cisco could use Mynaric’s technology to enhance its position in next-generation networks, including space-based systems.
    • Positioning: Looking to expand into emerging markets like satellite and aerospace networking.

5. Optical and Photonics Specialists

Companies specializing in lasers or photonics might acquire Mynaric to diversify or strengthen their market presence.

Key Candidates:

  1. Lumentum

    • Why? A leader in optical technologies, Lumentum could integrate Mynaric’s systems into its portfolio to serve aerospace and defense markets.
    • Positioning: Already a major player in photonics with resources for expansion.

  2. II-VI Incorporated (Now Coherent Corp.)

    • Why? A major photonics and materials company, Coherent Corp. could use Mynaric to expand into aerospace optical communication.
    • Positioning: Established in optical solutions with a focus on growth in high-tech markets.

  3. Thorlabs

    • Why? Known for advanced optical systems, Thorlabs could benefit from acquiring a company like Mynaric to enter the space and satellite communication market.
    • Positioning: Innovative but smaller-scale compared to others.

6. Private Equity and Investment Groups

Private equity firms with a focus on space, defense, or high-tech markets may see Mynaric as an attractive investment opportunity for its growth potential.

Key Candidates:

  1. Blackstone
  2. Carlyle Group
  3. Vista Equity Partners

These firms often acquire high-tech companies and scale them for eventual resale or IPO.

Conclusion

The companies best positioned to acquire Mynaric would likely be aerospace and defense giants (Airbus, Northrop Grumman, Lockheed Martin) or satellite operators (Amazon, SES, SpaceX). However, quantum technology companies (like ID Quantique) and optical specialists (like Lumentum or Coherent Corp.) could also find strategic value in integrating Mynaric’s capabilities into their portfolios. 

The final decision would depend on who sees the most synergy with Mynaric’s cutting-edge laser communication systems. More recently, Mynaric has been facing financial challenges. In December 2024, the company entered into negotiations with its primary lender to extend a $16.5 million bridge loan maturing on December 30, 2024, and to secure additional capital to support its production ramp and ongoing operations. This financial restructuring is being conducted under the German Corporate Stabilization and Restructuring Act (StaRUG).

Mynaric

Given these developments, it's plausible that companies with strategic interests in laser communication technology, such as those previously mentioned, might be monitoring Mynaric's situation. However, without official statements or confirmed reports, any assertions about acquisition interest remain speculative.

Ed Note:

Caution: In December 2024, Mynaric secured multiple bridge loans totaling over $20 million to address immediate working capital needs. The company also entered negotiations for further funding, contingent upon financial reorganization under Germany's StaRUG framework, which aims to facilitate corporate restructuring.

Full disclosure

We own shares of MYNA however, Our investment in MYNA is pure speculation and, one of the few penny stocks we own! 

-------------------------------------------------------------------------------------------------

Jan 30th update:

Recent Highlights & Potential Talks

  1. U.S. Defense & Government Opportunities

    • Mynaric continues to position itself for U.S. defense and government programs focusing on secure and high-throughput laser communications.
    • Multiple public statements indicate Mynaric is “in discussions” or “pursuing” additional defense-related contracts, but no explicit new partner names have been confirmed in official releases.

  2. Project and Contract Updates

    • Space Development Agency (SDA) / U.S. Space Force: While Mynaric has previously announced involvement with Space Development Agency-related efforts (for instance, providing optical terminals for test and demo satellites), many details remain under NDA. They have publicly noted ongoing expansions or negotiations for future tranches but have not disclosed fresh contract wins in official press releases that name new customers.
    • Lockheed Martin Relationship: Continues to be one of Mynaric’s most notable partnerships. While there have been follow-up references to “expanding collaboration” or “follow-on orders,” no brand-new programs or subcontracts have been identified publicly within the past few months.

  3. Product Evolution / Milestones

    • Mynaric announced in 2023 that it is ramping up serial production of its CONDOR optical communication terminals for satellites and is taking initial steps to further refine its HAWK terminals for airborne applications.
    • Often, these production milestones coincide with early-stage collaboration talks with large aerospace integrators or constellation operators, but specific new customers are frequently kept confidential until deals are finalized.

  4. Corporate Positioning and Funding

    • Mynaric remains vocal about raising capital for its production scale-up and R&D. While potential investors or strategic partners may be in talks, no official statement has named new, high-profile parties since Lockheed Martin’s equity investment in 2021.
    • The company has hinted at ongoing dialogues with “major industry players” without publicly naming them or detailing the status of those talks.

Where to Look for Fresh Updates

  1. Mynaric Investor Relations

    • The most direct, authoritative source. Check Mynaric’s press releases, financial reports, and investor presentations.

  2. U.S. SEC Filings (EDGAR)

    • As Mynaric is NASDAQ-listed (ticker “MYNA”), you can find updates in Form 6-K (periodic reports), 20-F (annual filings), and press-release exhibits, which sometimes contain details not highlighted in corporate announcements.

  3. German Filings & Announcements

    • Since Mynaric is headquartered in Germany, significant new contracts or deals might first appear in the German Federal Gazette (Bundesanzeiger) or through BaFin notifications.

  4. Space / Defense Industry News Outlets

    • Publications like SpaceNews, Defense News, Satellite Today, and Via Satellite often break stories about contract awards or near-term negotiations—particularly for military or government space programs.

Bottom Line

To date, there have been no major public announcements revealing brand-new named partnerships since the already-disclosed relationships (e.g., Lockheed Martin, SpaceLink, and others). Most signals of “talks” with new customers remain under wraps, likely due to non-disclosure agreements, competitive sensitivities, or standard procurement confidentiality, especially in the defense sector.

If you want to verify whether Mynaric has formalized any new deals—especially those not widely publicized—keep an eye on official press releases and government contract award notices.

Ed Note: Jan 31

We've been stopped out of our Myna shares at a loss of over 20% - Will keep it on our watch list!


Posted by at No comments:
Labels: , , , , , , , , , ,
Subscribe to: Posts (Atom)